Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.80 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835788 | 0.89 | PARP1 (1.00) | PARP1PARP2POLBESR2HTT | |
| SCHEMBL835746 | 0.83 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL835374 | 0.80 | PARP1 (1.00) | PARP1PARP2POLBESR2HTT | |
| SCHEMBL835994 | 0.77 | PARP1 (0.49) | PARP1POLBESR2HTTKDM4E | |
| SCHEMBL833220 | 0.77 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL833849 | 0.76 | PARP1 (1.00) | PARP1PARP2POLBESR2HTT | |
| SCHEMBL833334 | 0.75 | PARP1 (1.00) | PARP1PARP2POLBESR2HTT | |
| SCHEMBL1860022 | 0.75 | PARP1 (0.80) | PARP1PARP2 | |
| SCHEMBL1863422 | 0.74 | PARP1 (0.79) | PARP1PARP2 | |
| SCHEMBL1866667 | 0.74 | PARP1 (0.77) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | claimed |
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885POLB 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.